Use of Prophylactic Antibiotics in Asthma Exacerbation

20 slides not including title slide Quality and strength of evidence were to be evaluated according to these rating codes: I at least one properly designed randomized controlled trial II well designed controlled trails without randomizations III well designed cohort or case controlled analytic studies, preferably from more than one center or research group IV multiple time series with or without an intervention V opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees Interventions, practices and outcomes were to be based on the evidence that they are: a. Beneficial: their effectiveness has been demonstrated based on RCT’s; Evidence of harm is small compared with the benefits b. Likely to be beneficial: interventions for which effectiveness is less well documented than for those listed under beneficial c. Trade-off between benefits and harms: clinician and patients should weight the beneficial and harmful effects according to individual circumstances and priorities d. Unknown effectiveness: interventions for which there are insufficient data or data of inadequate quality e. Unlikely to be beneficial: interventions for which lack of effectiveness is less well established than for those listed under likely to be effective or harmful f. Likely to be ineffective or harmful: intervention for which ineffectiveness or harmfulness has been demonstrated by clear evidence